Mineralocorticoid receptor-associated hypertension and target organ damage: Clinical relevance for resistant hypertension in end stage renal disease

Current Hypertension Reviews

Volumn 8, Issue 4, 2012, Pages 267-275

  Rekhtman, Yelena ^a   Bomback, Andrew S ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Aldosterone; End organ damage; End stage renal disease; Hyperkalemia; Mineralocorticoid receptor blockade; Resistant hypertension

Indexed keywords

ALDOSTERONE; EPLERENONE; FUROSEMIDE; LOSARTAN; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD VESSEL INJURY; BORDERLINE HYPERTENSION; BREAST TENDERNESS; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; FOLLOW UP; GYNECOMASTIA; HEART INJURY; HOMEOSTASIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MASTALGIA; MONOTHERAPY; NONHUMAN; ORGAN INJURY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TISSUE INJURY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84873135573     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340212804546134     Document Type: Review

References (50)

1. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3(9): 486-92.
2. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351(13): 1285-95.
3. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41(7): 1148-55.
4. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40(2): 117-23.
5. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41(5): 1021-6.
6. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70(12): 2116-23.
7. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51(2):199-211.
8. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28(9): 2106-12.
9. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70(3): 536-42.
10. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24(11): 2285-92.
11. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55(1): 147-52.
12. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16(11 Pt 1): 925-30.
13. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49(4): 839-45.
14. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30(5): 418-24.
15. Pisoni R, Acelajado MC, Cartmill FR, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2012; 26(8): 502-6.
16. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensinaldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46(1): 94-101.
17. Bomback AS, Klemmer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012; 33(1-3):119-24.
18. Shavit L, Neykin D, Lifschitz M, Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients-a pilot study. Clin Nephrol 2011; 76(5): 388-95.
19. Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9(1): 13-8.
20. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283(5): H1802-10.
21. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63(5):1791-800.
22. Rocha R, Stier CT, Jr., Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141(10): 3871-8.
23. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31(1 Pt 2): 451-8.
24. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269(4 Pt 1): E657-62.
25. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103(4): 425-31.
26. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101(6): 594-7.
27. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109(23): 2857-61.
28. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10(1): 31-7.
29. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119(11): 912-9.
30. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91(6): 2214-7.
31. Vukusich A, Kunstmann S, Varela C, et al. A randomized, doubleblind, placebo-controlled trial of spironolactone on carotid intimamedia thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1380-7.
32. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709-17.
33. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309-21.
34. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients postmyocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol 2011; 58(19): 1958-66.
35. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1):11-21.
36. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114(5): 345-52.
37. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108(15):1831-8.
38. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41(1): 64-8.
39. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006; 33(5-6): 477-9.
40. Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009; 20(3): 392-7.
41. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110(8): 921-7.
42. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4(3): 542-51.
43. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1(5): 940-51.
44. Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18(11): 2359-63.
45. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003; 18(11): 2364-8.
46. Matsumoto Y, Kageyama S, Yakushigawa T, et al. Long-term lowdose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009; 114(1): 32-8.
47. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012; 81(10): 955-68.
48. Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh). 1984 54 Suppl 1:17-29.
49. Michea L, Vukusich A, Gonzalez M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int 2004; 66(4): 1647-53.
50. Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005; 45(7): 810-21.